TY - JOUR
T1 - Desmopressin in moderate hemophilia A patients: a treatment worth considering
AU - Loomans, Janneke I.
AU - Kruip, Marieke J. H. A.
AU - Carcao, Manuel
AU - Jackson, Shannon
AU - van Velzen, Alice S.
AU - Peters, Marjolein
AU - Santagostino, Elena
AU - Platokouki, Helen
AU - Beckers, Erik
AU - Voorberg, Jan
AU - van der Bom, Johanna G.
AU - Fijnvandraat, Karin
PY - 2018
Y1 - 2018
N2 - Desmopressin increases endogenous factor VIII levels in hemophilia A. Large inter-individual variation in the response to desmopressin is observed. Patients with a lower baseline factor VIII activity tend to show a reduced response. Therefore, desmopressin is less frequently used in moderate hemophilia A patients (baseline factor VIII activity 1-5 international units/deciliter), even though factor VIII levels may rise substantially in some of them. We aim to describe the response to desmopressin in moderate hemophilia A patients and to identify predictors. We selected data on 169 patients with moderate hemophilia from the multicenter RISE cohort study. Adequate response to desmopressin was defined as a peak factor VIII level ≥ 30 and excellent response as ≥ 50 international units/deciliter after desmopressin administration. We used univariate and multiple linear regression techniques to analyze predictors of the peak factor VIII level. Response was considered adequate in 68 patients (40%), of whom 25 showed excellent response (15%). Intravenous administration, age, pre-desmopressin factor VIII activity and Von Willebrand factor antigen, peak Von Willebrand factor activity and desmopressin induced rise in Von Willebrand factor antigen were significant predictors of peak factor VIII level and explained 65% of the inter-individual variation. In 40% of moderate hemophilia A patients, desmopressin response was adequate. Therefore, it is important not to refrain this group of patients from desmopressin responsiveness. Among the six predictors that we identified for desmopressin induced FVIII rise, factor VIII activity and desmopressin induced rise in Von Willebrand factor antigen had the strongest effect
AB - Desmopressin increases endogenous factor VIII levels in hemophilia A. Large inter-individual variation in the response to desmopressin is observed. Patients with a lower baseline factor VIII activity tend to show a reduced response. Therefore, desmopressin is less frequently used in moderate hemophilia A patients (baseline factor VIII activity 1-5 international units/deciliter), even though factor VIII levels may rise substantially in some of them. We aim to describe the response to desmopressin in moderate hemophilia A patients and to identify predictors. We selected data on 169 patients with moderate hemophilia from the multicenter RISE cohort study. Adequate response to desmopressin was defined as a peak factor VIII level ≥ 30 and excellent response as ≥ 50 international units/deciliter after desmopressin administration. We used univariate and multiple linear regression techniques to analyze predictors of the peak factor VIII level. Response was considered adequate in 68 patients (40%), of whom 25 showed excellent response (15%). Intravenous administration, age, pre-desmopressin factor VIII activity and Von Willebrand factor antigen, peak Von Willebrand factor activity and desmopressin induced rise in Von Willebrand factor antigen were significant predictors of peak factor VIII level and explained 65% of the inter-individual variation. In 40% of moderate hemophilia A patients, desmopressin response was adequate. Therefore, it is important not to refrain this group of patients from desmopressin responsiveness. Among the six predictors that we identified for desmopressin induced FVIII rise, factor VIII activity and desmopressin induced rise in Von Willebrand factor antigen had the strongest effect
U2 - https://doi.org/10.3324/haematol.2017.180059
DO - https://doi.org/10.3324/haematol.2017.180059
M3 - Article
C2 - 29305412
SN - 0390-6078
VL - 103
SP - 550
EP - 557
JO - Haematologica
JF - Haematologica
ER -